There was also obvious evidence of an association between XRCC6 rs5751129 polymorphism and increased cancer risk (C vs. T: OR = 1.93, 95% CI 1.42–2.63; CC vs. TT: OR = 1.60; 95% CI, 1.14–2.26; TC vs. TT: OR = 1.95, 95% CI 1.48–2.57; dominant model: OR = 2.00, 95% CI 1.50–2.67; recessive model: OR = 1.48, 95% CI 1.06–2.06) (Table 7). Here, XRCC6 is linked to cancer.